ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
In preclinical studies, PMN310 demonstrated the ability to selectively target and protect against pathogenic Aβ oligomers The IND clearance of…
